The metabolic and immunological characteristics of pregnant women with COVID-19 and their neonates.

Our aim was to investigate whether SARS-CoV-2 infection raised high risks of late pregnancy complications, and posed health problems in fetuses and neonates We analyzed the data of COVID-19 pregnant women with COVID-19 during late pregnancy and their neonates Eleven out of 16 (69%) pregnant women with COVID-19 had ++ or +++ of ketone body in urine The blood uric acid of pregnant patients was 334 μmol/L (IQR, 269-452) D-dimer and FDP in pregnant patients were 3 32 mg/L (IQR, 2 18-4 21) and 9 6 mg/L (IQR, 5 9-12 4) Results of blood samples collected at birth showed that 16 neonates had leukocytes (15 7 × 10(9)/L (IQR, 13 7-17 2)), neutrophils (11 1 × 10(9)/L (IQR, 9 2-13 2)), CK (401 U/L (IQR, 382-647)), and LDH (445 U/L (IQR, 417-559)) Twenty-four hours after birth, a neonate from COVID-19 woman had fever and positive of SARS-CoV-2 gene Another woman had strongly positive for SARS-CoV-2 gene (+++) for 4 weeks, and delivered one neonate who had SARS-CoV-2 IgM (46 AU/mL) and IgG (140 AU/mL) on day 1 after birth In the third trimester, COVID-19 infection in pregnant patients raised high risks of ketonuria, hypercoagulable state, and hyperfibrinolysis, which may lead to severe complications COVID-19 increased the inflammatory responses of placenta, and fetuses and neonates had potential organ dysregulation and coagulation disorders There was a potential intrauterine transmission while pregnant women had high titer of SARS-CoV-2, but it is necessary to detect SARS-CoV-2 in the blood cord, placenta, and amniotic fluid to further confirm intrauterine infection of fetuses